INNOVUS PHARMACEUTICALS, INC. - FORM 10-K - EX-32.1 - CERTIFICATION OF THE REGISTRANT?S PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SS. 1350, AS ADOPTED PURSUANT - March 31, 2015

Attached files

file filename
EX-31.2 - CERTIFICATION OF THE REGISTRANT?S PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15(D)-14(A). - INNOVUS PHARMACEUTICALS, INC.ex31-2.htm
EX-23.1 - CONSENT OF EISNERAMPER LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. - INNOVUS PHARMACEUTICALS, INC.ex23-1.htm
EX-21.1 - LIST OF SUBSIDIARIES - INNOVUS PHARMACEUTICALS, INC.ex21-1.htm
EX-31.1 - CERTIFICATION OF THE REGISTRANT?S PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15(D)-14(A), AS ADOPTED - INNOVUS PHARMACEUTICALS, INC.ex31-1.htm
EX-14.1 - CODE OF ETHICS. - INNOVUS PHARMACEUTICALS, INC.ex14-1.htm
EX-10.24 - OFFER LETTER, DATED FEBRUARY 6, 2014, BETWEEN INNOVUS PHARMACEUTICALS, INC. AND LYNNETTE DILLEN. - INNOVUS PHARMACEUTICALS, INC.ex10-24.htm
EXCEL - IDEA: XBRL DOCUMENT - INNOVUS PHARMACEUTICALS, INC.Financial_Report.xls
10-K - FORM 10-K - INNOVUS PHARMACEUTICALS, INC.innv10k_dec312014.htm
Exhibit 32.1
 
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Innovus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bassam Damaj, principal executive officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that:
 
1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
2.          The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.
 
March 31, 2015
/s/ Bassam Damaj
 
Bassam Damaj
 
President and Chief Executive Officer
 
(Principal Executive Officer)
 
In connection with the Annual Report of Innovus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lynnette Dillen, principal financial and accounting officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that:
 
1.          The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
2.          The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.
 
March 31, 2015
/s/ Lynnette Dillen
 
Lynnette Dillen
 
Executive Vice President and Chief Financial Officer
 
(Principal Financial and Accounting Officer)

INNOVUS PHARMACEUTICALS, INC. Reports